ABSTRACT
Deficits in social memory, cognition, and aberrant responses to stimulants are common among persons affected by schizophrenia and other conditions with a presumed developmental etiology. We previously found that expression changes in the adenosine metabolizing enzyme adenosine kinase (ADK) in the adult brain are associated with deficits in various cognitive domains. To distinguish between developmental and adult functions of ADK, we used two transgenic mouse lines with widespread disruption of ADK expression in the adult brain, but differences in the onset of ADK deletion. Specifically, we compared Nestin-Cre+/-:ADK-floxfl/fl (ADKΔBrain) mice with global loss of ADK in the whole brain, beginning in mid-gestation and persisting for life, with Gfa2-Cre+/-:ADK-floxfl/fl (ADKΔAstro) mice that have normal ADK expression throughout development, but lose astrocyte-specific ADK-expression in young adulthood. Because ADK-expression in adulthood is generally confined to astrocytes, adult ADKΔAstro mice show a similar expression profile of ADK in key areas of the brain related to neuropsychiatric behavior, compared to adult ADKΔBrain mice. We sought to determine a neurodevelopmental role of ADK on the expression of psychiatric behaviors in adult male and female mice. Adult ADKΔBrain mice showed significant deficits in social memory in males, significant contextual learning impairments in both sexes, and a hyper-responsiveness to amphetamine in males. In contrast, ADKΔAstro mice showed normal social memory and contextual learning but hypo-responsiveness to amphetamine in males. Our results demonstrate a key developmental role of ADK in mediating behaviors in adulthood related to neuropsychiatric disease and support the greater prevalence of these disorders among males.
Subject(s)
Adenosine Kinase/physiology , Central Nervous System Sensitization/genetics , Learning/physiology , Memory/physiology , Sex Characteristics , Adenosine Kinase/genetics , Age Factors , Amphetamine/pharmacology , Animals , Female , HSP40 Heat-Shock Proteins/genetics , Male , Mice , Mice, Transgenic , Nestin/geneticsABSTRACT
We have very little information about the metabolomic changes that mediate neurobehavioral responses, including addiction. It was possible that opioid-induced metabolomic changes in brain could mediate some of the pharmacodynamic effects of opioids. To investigate this, opiate-induced brain metabolomic responses were profiled using a semi-targeted method in C57BL/6 and 129Sv1 mice, which exhibit extreme differences in their tendency to become opiate dependent. Escalating morphine doses (10-40 mg/kg) administered over a 4-day period selectively induced a twofold decrease (p<0.00005) in adenosine abundance in the brainstem of C57BL/6 mice, which exhibited symptoms of narcotic drug dependence; but did not decrease adenosine abundance in 129Sv1 mice, which do not exhibit symptoms of dependence. Based on this finding, the effect of adenosine on dependence was investigated in genetically engineered mice with alterations in adenosine tone in the brain and in pharmacologic experiments. Morphine withdrawal behaviors were significantly diminished (p<0.0004) in genetically engineered mice with reduced adenosine tone in the brainstem, and by treatment with an adenosine receptor(1) (A(1)) agonist (2-chloro-N6-cyclopentyladenosine, 0.5mg/kg) or an A(2a) receptor (A(2a)) antagonist (SCH 58261, 1mg/kg). These results indicate that adenosine homeostasis plays a crucial role in narcotic drug responses. Opiate-induced changes in brain adenosine levels may explain many important neurobehavioral features associated with opiate addiction and withdrawal.
Subject(s)
Adenosine/metabolism , Analgesics, Opioid/pharmacology , Brain/metabolism , Morphine Dependence/metabolism , Morphine/pharmacology , Animals , Behavior, Addictive/genetics , Behavior, Addictive/metabolism , Brain/drug effects , Male , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Transgenic , Morphine Dependence/genetics , Narcotics/pharmacology , Species SpecificityABSTRACT
The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties from the IUPHAR database. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full. This compilation of the major pharmacological targets is divided into seven areas of focus: G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone receptors, transporters and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. A new landscape format has easy to use tables comparing related targets. It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in previous Guides to Receptors & Channels. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive database updates.
Subject(s)
Databases, Pharmaceutical , Molecular Targeted Therapy , Pharmacology , Humans , Ligands , Pharmaceutical Preparations/chemistryABSTRACT
The neuromodulator adenosine maintains brain homeostasis and regulates complex behaviour via activation of inhibitory and excitatory adenosine receptors (ARs) in a brain region-specific manner. AR antagonists such as caffeine have been shown to ameliorate cognitive impairments in animal disease models but their effects on learning and memory in normal animals are equivocal. An alternative approach to reduce AR activation is to lower the extracellular tone of adenosine, which can be achieved by up-regulating adenosine kinase (ADK), the key enzyme of metabolic adenosine clearance. However, mice that globally over-express an Adk transgene ('Adk-tg' mice) were devoid of a caffeine-like pro-cognitive profile; they instead exhibited severe spatial memory deficits. This may be mechanistically linked to cortical/hippocampal N-methyl-d-aspartate receptor (NMDAR) hypofunction because the motor response to acute MK-801 was also potentiated in Adk-tg mice. Here, we evaluated the extent to which the behavioural phenotypes of Adk-tg mice might be modifiable by up-regulating adenosine levels in the cortex/hippocampus. To this end, we investigated mutant 'fb-Adk-def' mice in which ADK expression was specifically reduced in the telencephalon leading to a selective increase in cortical/hippocampal adenosine, while the rest of the brain remained as adenosine-deficient as in Adk-tg mice. The fb-Adk-def mice showed an even greater impairment in spatial working memory and a more pronounced motor response to NMDAR blockade than Adk-tg mice. These outcomes suggest that maintenance of cortical/hippocampal adenosine homeostasis is essential for effective spatial memory and deviation in either direction is detrimental with increased expression seemingly more disruptive than decreased expression.
Subject(s)
Adenosine Kinase/metabolism , Adenosine/metabolism , Brain/metabolism , Homeostasis/physiology , Memory, Short-Term/physiology , Animals , Maze Learning/physiology , Mice , Mice, Mutant Strains , Receptors, N-Methyl-D-Aspartate/metabolismABSTRACT
ATP and adenosine are purines that play dual roles in cell metabolism and neuronal signaling. Acting at the A(1) receptor (A(1)R) subtype, adenosine acts directly on neurons to inhibit excitability and is a powerful endogenous neuroprotective and anticonvulsant molecule. Previous research showed an increase in ATP and other cell energy parameters when an animal is administered a ketogenic diet, an established metabolic therapy to reduce epileptic seizures, but the relationship among purines, neuronal excitability and the ketogenic diet was unclear. Recent work in vivo and in vitro tested the specific hypothesis that adenosine acting at A(1)Rs is a key mechanism underlying the success of ketogenic diet therapy and yielded direct evidence linking A(1)Rs to the antiepileptic effects of a ketogenic diet. Specifically, an in vitro mimic of a ketogenic diet revealed an A(1)R-dependent metabolic autocrine hyperpolarization of hippocampal neurons. In parallel, applying the ketogenic diet in vivo to transgenic mouse models with spontaneous electrographic seizures revealed that intact A(1)Rs are necessary for the seizure-suppressing effects of the diet. This is the first direct in vivo evidence linking A(1)Rs to the antiepileptic effects of a ketogenic diet. Other predictions of the relationship between purines and the ketogenic diet are discussed. Taken together, recent research on the role of purines may offer new opportunities for metabolic therapy and insight into its underlying mechanisms.
Subject(s)
Anticonvulsants/therapeutic use , Diet, Ketogenic , Epilepsy/diet therapy , Neurons/metabolism , Purines/therapeutic use , Animals , Humans , Ketone Bodies/metabolism , Purines/metabolismABSTRACT
Despite major advances in a variety of neuroscientific research fields, the majority of neurodegenerative and neurological diseases are poorly controlled by currently available drugs, which are largely based on a neurocentric drug design. Research from the past 5 years has established a central role of glia to determine how neurons function and, consequently, glial dysfunction is implicated in almost every neurodegenerative and neurological disease. Glial cells are key regulators of the brain's endogenous neuroprotectant and anticonvulsant adenosine. This review will summarize how glial cells contribute to adenosine homeostasis and how glial adenosine receptors affect glial function. We will then move on to discuss how glial cells interact with neurons and the vasculature, and outline new methods to study glial function. We will discuss how glial control of adenosine function affects neuronal cell death, and its implications for epilepsy, traumatic brain injury, ischemia, and Parkinson's disease. Eventually, glial adenosine-modulating drug targets might be an attractive alternative for the treatment of neurodegenerative diseases. There are, however, several major open questions that remain to be tackled.
Subject(s)
Adenosine/metabolism , Neuroglia/metabolism , Anticonvulsants/pharmacology , Apoptosis , Humans , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/etiology , Neurodegenerative Diseases/metabolism , Neuroglia/physiology , Neurons/cytology , Receptors, Purinergic P1/metabolism , Signal TransductionABSTRACT
Converging evidence from pharmacological and molecular studies has led to the suggestion that inhibition of glycine transporter 1 (GlyT1) constitutes an effective means to boost N-methyl-d-aspartate receptor (NMDAR) activity by increasing the extra-cellular concentration of glycine in the vicinity of glutamatergic synapses. However, the precise extent and limitation of this approach to alter cognitive function, and therefore its potential as a treatment strategy against psychiatric conditions marked by cognitive impairments, remain to be fully examined. Here, we generated mutant mice lacking GlyT1 in the entire forebrain including neurons and glia. This conditional knockout system allows a more precise examination of GlyT1 downregulation in the brain on behavior and cognition. The mutation was highly effective in attenuating the motor-stimulating effect of acute NMDAR blockade by phencyclidine, although no appreciable elevation in NMDAR-mediated excitatory postsynaptic currents (EPSC) was observed in the hippocampus. Enhanced cognitive performance was observed in spatial working memory and object recognition memory while spatial reference memory and associative learning remained unaltered. These findings provide further credence for the potential cognitive enhancing effects of brain GlyT1 inhibition. At the same time, they indicated potential phenotypic differences when compared with other constitutive and conditional GlyT1 knockout lines, and highlighted the possibility of a functional divergence between the neuronal and glia subpopulations of GlyT1 in the regulation of learning and memory processes. The relevance of this distinction to the design of future GlyT1 blockers as therapeutic tools in the treatment of cognitive disorders remains to be further investigated.
Subject(s)
Glycine Plasma Membrane Transport Proteins/genetics , Memory , Prosencephalon/physiology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Amphetamine/pharmacology , Animals , Down-Regulation , Excitatory Postsynaptic Potentials , Female , Glycine/metabolism , Glycine Plasma Membrane Transport Proteins/biosynthesis , Hippocampus/physiology , Learning , Male , Mice , Mice, Knockout , Motor Activity/drug effects , Mutation , Phencyclidine/pharmacology , Prosencephalon/drug effects , Prosencephalon/metabolism , Psychomotor Performance , Receptors, N-Methyl-D-Aspartate/biosynthesis , Recognition, Psychology , Synaptic TransmissionABSTRACT
Adenosine is a potent modulator of excitatory neurotransmission, especially in seizure-prone regions such as the hippocampal formation. In adult brain ambient levels of adenosine are controlled by adenosine kinase (ADK), the major adenosine-metabolizing enzyme, expressed most strongly in astrocytes. Since ontogeny of the adenosine system is largely unknown, we investigated ADK expression and cellular localization during postnatal development of the mouse brain, using immunofluorescence staining with cell-type specific markers. At early postnatal stages ADK immunoreactivity was prominent in neurons, notably in cerebral cortex and hippocampus. Thereafter, as seen best in hippocampus, ADK gradually disappeared from neurons and appeared in newly developed nestin- and glial fibrillary acidic protein (GFAP)-positive astrocytes. Furthermore, the region-specific downregulation of neuronal ADK coincided with the onset of myelination, as visualized by myelin basic protein staining. After postnatal day 14 (P14), the transition from neuronal to astrocytic ADK expression was complete, except in a subset of neurons that retained ADK until adulthood in specific regions, such as striatum. Moreover, neuronal progenitors in the adult dentate gyrus lacked ADK. Finally, recordings of excitatory field potentials in acute slice preparations revealed a reduced adenosinergic inhibition in P14 hippocampus compared with adult. These findings suggest distinct roles for adenosine in the developing and adult brain. First, ADK expression in young neurons may provide a salvage pathway to utilize adenosine in nucleic acid synthesis, thus supporting differentiation and plasticity and influencing myelination; and second, adult ADK expression in astrocytes may offer a mechanism to regulate adenosine levels as a function of metabolic needs and synaptic activity, thus contributing to the differential resistance of young and adult animals to seizures.
Subject(s)
Adenosine Kinase/metabolism , Astrocytes/enzymology , Brain , Gene Expression Regulation, Developmental/physiology , Neurons/enzymology , Age Factors , Animals , Animals, Newborn , Brain/cytology , Brain/enzymology , Brain/growth & development , Cell Count/methods , Excitatory Postsynaptic Potentials/physiology , Excitatory Postsynaptic Potentials/radiation effects , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry/methods , In Vitro Techniques , Mice , Myelin Basic Protein/metabolism , Neurons/physiology , Patch-Clamp Techniques/methods , Phosphopyruvate Hydratase/metabolismABSTRACT
Adenosine is an inhibitor of neuronal activity in the brain. The local release of adenosine from grafted cells was evaluated as an ex vivo gene therapy approach to suppress synchronous discharges and epileptic seizures. Fibroblasts were engineered to release adenosine by inactivating the adenosine-metabolizing enzymes adenosine kinase and adenosine deaminase. After encapsulation into semipermeable polymers, the cells were grafted into the brain ventricles of electrically kindled rats, a model of partial epilepsy. Grafted rats provided a nearly complete protection from behavioral seizures and a near-complete suppression of afterdischarges in electroencephalogram recordings, whereas the full tonic-clonic convulsions in control rats remained unaltered. Thus, the local release of adenosine resulting in adenosine concentrations <25 nM at the site of action is sufficient to suppress seizure activity and, therefore, provides a potential therapeutic principle for the treatment of drug-resistant partial epilepsies.
Subject(s)
Adenosine Deaminase/metabolism , Adenosine Kinase/metabolism , Adenosine/physiology , Brain/metabolism , Cell Transplantation , Kindling, Neurologic/physiology , Seizures/therapy , Adenosine/metabolism , Adenosine Deaminase/deficiency , Adenosine Deaminase/genetics , Adenosine Kinase/genetics , Aggression , Animals , Brain/cytology , Cell Line , Cricetinae , Epilepsies, Partial/therapy , Exploratory Behavior , Fibroblasts/cytology , Fibroblasts/physiology , Genetic Therapy , Kindling, Neurologic/drug effects , Male , Mice , Mice, Knockout , Motor Activity , Phenytoin/pharmacology , Rats , Rats, Inbred Strains , Seizures/physiopathology , Social Behavior , Xanthines/pharmacologyABSTRACT
Adenosine, an endogenous inhibitory neuromodulator in the central nervous system, exerts anticonvulsant activity that is largely based on the inhibition of the release of excitatory amino acids. As a novel approach to treat pharmacoresistant partial epilepsies, the grafting of adenosine-releasing cells is foreseen to provide a local and sustained source of adenosine. The feasibility of this cell-based therapy was investigated in the present study by the intraventricular implantation of synthetic polymers that release adenosine. Kindled rats with a ventricular implant of an adenosine-releasing polymer showed a profound reduction of seizure activity. This was demonstrated not only by a 75% reduction of grade 5 seizures but also by a reduction of the amplitude and duration of afterdischarges in electroencephalographic (EEG) recordings. Kindled control rats that were implanted with bovine serum albumin (BSA)-containing polymers or were sham operated, continued to show their presurgery seizure pattern. Adenosine displayed antiepileptic activity when released in an amount of 20-50 ng per day. This finding sets the target for the required amount of adenosine to be released from future adenosine-releasing cells for antiepileptic therapy. The present results clearly support the feasibility of a novel therapy for epilepsy based on adenosine-releasing cells.
Subject(s)
Adenosine/therapeutic use , Anticonvulsants/therapeutic use , Cerebral Ventricles , Kindling, Neurologic/drug effects , Neuroprotective Agents/therapeutic use , Seizures/prevention & control , Adenosine/administration & dosage , Adenosine/pharmacology , Animals , Anticonvulsants/administration & dosage , Anticonvulsants/pharmacology , Biocompatible Materials , Cattle , Delayed-Action Preparations , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Implants , Electroencephalography/drug effects , Epilepsy, Temporal Lobe , Feasibility Studies , Male , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacology , Polyvinyls , Rats , Rats, Sprague-Dawley , Serum Albumin, BovineABSTRACT
Myelination is an important developmental process of the central (CNS) and peripheral nervous system (PNS). To unravel the functions of the two dominant myelin proteins in the CNS, proteolipid protein (PLP) and myelin basic protein (MBP), we generated and characterized the homozygous double mutant mouse line (plp-/-, mbp-/-), which is viable and fertile. Plasma membrane processes of oligodendrocytes deficient in PLP and MBP, but not in myelin-associated glycoprotein (MAG), spirally wrap large diameter axons, tightly adhering at their extracytosolic surfaces and forming a pseudo-compacted myelin. Neuromotor activity and coordination are considerably improved compared to the shiverer trait.
Subject(s)
Myelin Basic Protein/physiology , Myelin Proteolipid Protein/physiology , Animals , Central Nervous System/physiology , Central Nervous System/ultrastructure , Female , Galactosyltransferases/genetics , Ganglioside Galactosyltransferase , Genotype , Male , Mice , Mice, Knockout , Microscopy , Microscopy, Electron , Mutation , Myelin Basic Protein/deficiency , Myelin Basic Protein/genetics , Myelin Proteolipid Protein/deficiency , Myelin Proteolipid Protein/genetics , Myelin Sheath/metabolism , Myelin-Associated Glycoprotein/genetics , RNA/analysisABSTRACT
The conduction velocity of action potentials in nerve fibres is proportional to degree of myelination. Here we studied the influence of myelin ultrastructure on the compound action potential conduction velocity in optic nerves of the proteolipid protein (PLP)-deficient mouse model, which displays loose myelination in central fibres. We show that a myelin decompaction leads to a suboptimal conduction velocity. The significance of myelin ultrastructure for conduction of action potential in the optic nerve is discussed.
Subject(s)
Action Potentials/physiology , Myelin Sheath/physiology , Neural Conduction/physiology , Optic Nerve/physiology , Age Factors , Animals , Central Nervous System/anatomy & histology , Electrophysiology , Mice , Myelin Sheath/ultrastructure , Optic Nerve/ultrastructureABSTRACT
We have studied the molecular function of proteolipid protein (PLP), the main integral membrane protein of CNS myelin, by generating mice lacking PLP expression. Here, we demonstrate that these PLP-minus mice show no pleiotropism as mice carrying point mutations within the PLP gene. The expression of other myelin genes (myelin basic protein, MBP; myelin associated glycoprotein, MAG; UDP-galactose-ceramide galactosyl transferase, CGT) is unimpaired on the RNA level. Protein level immunofluorescence analysis by confocal microscopy reveals that in PLP-minus mice there is a complete absence of PLP, a scattered appearance of MBP, and MAG expressed more widely in regions lacking MBP staining, which may be a compensatory mechanism. In electron microscopy the myelin lamellae of the ensheathed CNS axons are loosely wrapped with wide extracellular spaces between turning loops. Intraperiod dense lines are missing. The lateral loops of the paranode form regular axoglial junctions. In PLP-minus mice axons form regular axoglial junctions. In PLP-minus mice axons with large diameters are loosely myelinated, whereas small axons remain unmyelinated. Functionally, the mutant mice show deficits in their locomotor activity. We propose that adhesion properties of the extracellular domains of PLP are responsible for the tight apposition of the plasma membrane processes of oligodendrocytes wrapping axons to form the compact myelin sheath.
Subject(s)
Central Nervous System/physiology , Myelin Proteins/physiology , Myelin Sheath/physiology , Nerve Tissue Proteins , Adhesiveness , Animals , Base Sequence , Fluorescent Antibody Technique , Gene Expression , Heterozygote , Homozygote , Lipid Metabolism , Mice , Mice, Transgenic/genetics , Microscopy, Confocal , Molecular Probes/genetics , Molecular Sequence Data , Myelin Proteins/deficiency , Myelin Proteins/genetics , Myelin Proteins/metabolism , Myelin Proteolipid Protein , Myelin Sheath/ultrastructure , Oligodendroglia/physiologyABSTRACT
The isoproteins proteolipid protein (PLP) and DM20, the two major integral membrane proteins of central nervous system (CNS) myelin, are encoded by a single gene on the X chromosome and show a different developmental expression pattern. To investigate their functions in myelin structure and myelination, we produced transgenic mice carrying a targeted alteration of the X chromosome-linked Plp gene containing a deletion within exon III, mimicking DM20, and a neo cassette in reverse orientation within intron III. Here we show that the antisense integration of the neo cassette disrupts the expression of the Plp gene. The ultrastructure of the multilayer myelin sheath of all axons in the CNS of hemizygous male or homozygous female PLP/DM20-deficient mice is highly disordered. The apposition of the extracytoplasmic surfaces and thereby the intraperiod dense line is lacking. The disrupted assembly of the myelin sheath leads to a profound reduction of conductance velocities of CNS axons, impairments in neuromotor coordination, and behavioral changes.
Subject(s)
Myelin Proteins/deficiency , Myelin Sheath/ultrastructure , Animals , Behavior, Animal/physiology , Brain/metabolism , Female , Gene Expression , Male , Mice , Mice, Knockout/anatomy & histology , Mice, Knockout/physiology , Microscopy, Electron , Mutagenesis, Insertional , Myelin Proteins/physiology , Myelin Proteolipid Protein , Neural Conduction , Optic Nerve/ultrastructure , RNA, Messenger/geneticsABSTRACT
The expression of the proteolipid protein (PLP) gene of the myelin deficient (md) and normal rat was studied during the myelination period. The sizes of the PLP transcripts (1.6 and 3.2 kb) in the md and normal rat were identical although the md PLP messenger RNA level was extremely reduced as shown by in situ hybridization and Northern blot hybridization analysis. The structure of the md proteolipid protein gene was analyzed on the cDNA and genomic level. The molecular basis of the myelin deficiency phenotype has been elucidated: a point mutation in exon III (A----C transversion) verified by cDNA and genomic DNA sequencing causes a mutation of Thr75 to Pro and creates an additional AvaII restriction site in exon III of the md rat. The threonine to proline mutation located within the second transmembranal alpha-helix might induce a conformational change and thereby prohibit the integration of PLP into the membrane with the clinical manifestation of dysmyelination leading to premature death within 3-6 weeks.